title: Pretreatment with buflomedil enhances ventricular function by reducing the dysfunctional area after transient coronary artery occlusion.
abstract: OBJECTIVE
  The aim was to evaluate whether buflomedil (a drug used to treat peripheral vascular disease and which has a number of pharmacological actions potentially beneficial to dysfunctional myocardium) would preserve myocardial function after transient coronary artery occlusion followed by reperfusion.
  
  
  METHODS
  The physiological response to a 15 min balloon occlusion of the left anterior descending coronary artery followed by 1 h of reperfusion was monitored in 17 placebo treated dogs and compared with that of 15 dogs which received 10 mg.kg-1 of buflomedil. Buflomedil or its vehicle were given intravenously. Myocardial blood flow was assessed with radiolabelled microspheres and cardiac function was evaluated with quantitative contrast left ventriculography.
  
  
  RESULTS
  Buflomedil did not affect baseline haemodynamic variables or contractile function. At the end of occlusion, there was no difference between dogs receiving vehicle compared with those receiving drug with respect to ejection fraction [33(SD 11)% v 34(11)%] or transmural blood flow [0.23(0.11) v 0.28(0.14) ml.g-1 x min-1]. However, at 30 min after reperfusion, ejection fraction was 89% of normal in the buflomedil group compared with 69% of normal in the placebo group (p < 0.03). This difference was sustained 60 min after reperfusion, and was due in part to slightly enhanced flow during reperfusion and a decrease in the dysfunctional area (16 compared with 28 chords lower than -2 SD from the mean, p < 0.04) in the hearts of dogs receiving buflomedil. Areas at risk were equivalent (15.9% and 15.8% of the left ventricle, respectively).
  
  
  CONCLUSIONS
  The results suggest that buflomedil and agents with similar modes of action may be beneficial in preserving ventricular function after transient ischaemia followed by reperfusion.
authors.affiliation: Cardiovascular Division, Washington University School of Medicine, St Louis, MO 63110.
authors.forename: C J
authors.initials: CJ
authors.lastname: Weinheimer
authors.forename: P D
authors.initials: PD
authors.lastname: Toeniskoetter
authors.forename: A
authors.initials: A
authors.lastname: Conversano
authors.forename: P
authors.initials: P
authors.lastname: Pelat
authors.forename: A Y
authors.initials: AY
authors.lastname: Dubourg
authors.forename: S R
authors.initials: SR
authors.lastname: Bergmann
mesh_terms: D000818:Animals; D002302:Cardiac Output / Q000187:drug effects; D003326:Coronary Circulation / Q000502:physiology*; D004285:Dogs; D007511:Ischemia / Q000503:physiopathology; D009200:Myocardial Contraction / Q000187:drug effects; D015425:Myocardial Reperfusion; D011759:Pyrrolidines / Q000494:pharmacology*; D013318:Stroke Volume / Q000187:drug effects; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D011759:Pyrrolidines; C010651:buflomedil